ADRX · ADARx Pharmaceuticals, Inc.
Market Cap
$1.83B
Shares
106.80M
Volume · Oct 22
108.6K
Avg daily vol (19 sessions)
859.8K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$17.13
Open$17.58
Day$17.00–18.17
Available close range$17.13–20.64
Avg vol available · 19d860K
Short int1.2M · 1.1% float · 1.7d
Short vol53%
DataSep 2026–Oct 2026
The closing range uses available history since Sep 25, 2026; less than a full year is stored.
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
1.1%
Latest settlement · 1.7 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Limited
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
RSI (14)
35
neutral
52-week position
0%
near low
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
No 13F holder data
Insider flow
Accumulating
Net +$43.4M over 90 days · 0% sells
Short interest
Rising
1.09% of float · 1.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Squeeze score
46
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
49%
annualized · 1-yr
Max drawdown
−17%
past year
ATR
9.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
RSI (14)
35
Neutral
52-week position
0%
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
No 13F holder data
Insider flow
Accumulating
Net +$43.4M over 90 days · 0% sells
Short interest
Rising
1.09% of float · 1.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its available closing range
Range low $17
Now $17 · 0%
Range high $21
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ADRX
this stock
ADARx Pharmaceuticals, Inc.
|
$1.83B | — | — | — | 1.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.14B | +15.7% | +46.2% | 31.3 | 1.8% |
|
MRNA
Moderna, Inc.
|
$98.14B | +733.5% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.95B | +4.4% | +20.8% | 20.0 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.22B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Smart Money
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ADRX | -3.9% | — | — | -14.1% | — |
| SPY | +0.5% | +0.7% | +7.6% | +1.4% | +13.4% |
| vs SPY | -4.4% | — | — | -15.5% | — |